Healthcare industry

BorgWarner issues warning to Delphi about the latter drawing from its credit facility, as fears of the coronavirus spreads. The two companies are working towards closing a deal. On the middle market side, we check in with dealmakers from Alvarez & Marsal, Riverside, M33 Growth and Paul Hastings about the potential impact.

For risk managers, Covid-19 presents a stark reminder of the need to prepare for threats proactively.

Federal government stimulus measures could be on the way, as volatility in the stock markets continue and coronavirus spreads. We check in with dealmakers from Riverside, Merrill Corp. and Paul Hastings about the potential impact on mid-market M&A. In PE news, Blackstone backs healthcare technology company HealthEdge.

Thermo Fisher buys coronavirus test maker Qiagen in biggest healthcare of the deal of the year. Bregal Sagemount raises third fund. In more PE news, AEI, GTCR and FP make deals.

When a new coronavirus emerged out of China in January, Qiagen got to work on a test to detect the virus in bodily fluids. The test is now being evaluated at four hospitals in China and one in France. The diagnostic gives results in about one hour.

The tech conglomerate is using its recent deals for Health Navigator and PillPack to launch new software services in healthcare.

Confronted with the rare prospect of defeat on Capitol Hill, Blackstone and KKR unleashed a national advertising blitz last year against legislation that threatened their investments in healthcare companies.

"I’m particularly proud of the work we’re doing there."

Weekly wrap: Astellas buys Audentes Therapeutics. Cleveland-Cliffs purchases AK Steel. PepsiCo acquires BFY Brands.

NovaQuest and Wellington Management raise healthcare-related funds. Asterion, led by former KKR executives, closes first fund. CD&R bets on growth in the medical aesthetics sector. Advent buys haircare brand. GF Data provides third quarter lower middle-market valuations update.